Valuation: Alvotech

Market Cap 1.65B 1.47B 1.36B 1.24B 2.31B 157B 2.35B 16.42B 6.49B 82.05B 6.19B 6.06B 260B P/E 2026 *
110x
P/E 2027 * 15.4x
Enterprise Value 2.72B 2.44B 2.25B 2.04B 3.82B 259B 3.88B 27.12B 10.73B 136B 10.23B 10.01B 429B EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.44x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-0.11%
1 week-8.15%
Current month-20.34%
1 month-19.65%
3 months+50.98%
6 months+36.69%
Current year-9.94%
1 week 4.52
Extreme 4.52
5.24
1 month 4.52
Extreme 4.52
6.53
Current year 2.94
Extreme 2.94
6.53
1 year 2.94
Extreme 2.94
8.15
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 57 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
01/04/26 Free

Chief Executive Officer

117,271 0.0355%
01/04/26 Sell

Founder

318,000 0.0963%
01/04/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%-8.15%-45.00%-45.96% 1.65B
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.67%-0.67%+9.06%+76.30% 54.57B
-0.69%+0.83%+8.92%+100.32% 53.59B
+1.71%+3.52%+27.53%+54.10% 45.03B
-3.81%-6.22%+14.31%+111.54% 42.17B
-0.77%-6.60%+216.57%+886.46% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.70%-10.77%+19.80%-6.47% 24.01B
+0.15%+14.22%+58.93%+48.08% 26.5B
Average -0.83%+1.17%+36.61%+134.29% 38.49B
Weighted average by Cap. -0.69%+2.22%+42.79%+153.07%

Financials

2026 *2027 *
Net sales 653M 584M 540M 489M 915M 62.1B 930M 6.5B 2.57B 32.48B 2.45B 2.4B 103B 786M 703M 650M 589M 1.1B 74.77B 1.12B 7.82B 3.09B 39.11B 2.95B 2.89B 124B
Net income 2.25M 2.01M 1.86M 1.68M 3.15M 214M 3.2M 22.36M 8.84M 112M 8.43M 8.25M 354M 80.1M 71.62M 66.26M 60M 112M 7.62B 114M 797M 315M 3.99B 301M 294M 12.62B
Net Debt 1.08B 962M 890M 806M 1.51B 102B 1.53B 10.71B 4.24B 53.52B 4.04B 3.95B 169B 1.06B 944M 874M 791M 1.48B 100B 1.5B 10.51B 4.16B 52.54B 3.96B 3.88B 166B
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26/10/26 $4.620 +0.87% 584,888
23/10/26 $4.580 -4.38% 666,200
22/10/26 $4.790 -6.63% 926,997
21/10/26 $5.130 +0.20% 480,527
20/10/26 $5.120 +1.79% 1,302,515
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.620USD
Average target price
7.200USD
Spread / Average Target
+55.84%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech
  1. Stock Market
  2. Stocks
  3. ALVO Stock